Legal / IP

Transcenta Granted Chinese Invention Patent for Anti‑CLDN18.2 Antibodies – Protecting the Companion Diagnostic for Osemitamab (TST001) in Gastric Cancer
HKG: 6628Patents

Transcenta Granted Chinese Invention Patent for Anti‑CLDN18.2 Antibodies – Protecting the Companion Diagnostic for Osemitamab (TST001) in Gastric Cancer

Transcenta Holding Limited (HKG: 6628) announced that it has been granted an invention patent by the China National Intellectual Property Administration (CNIPA) covering the anti-CLDN18.2 antibodies independently developed by the…

Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA

WuXi AppTec Wins Preliminary Injunction Against DoD 1260H Designation

WuXi AppTec Wins Preliminary Injunction Against DoD 1260H Designation

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
FibroGenKind Pharmaceuticals

Kind Pharmaceuticals Resolves Trade Secrets Dispute with Fibrogen Amid HIF-PHI Pipeline Development

Patents

China’s CNIPA and USPTO Pledge to Deepen Intellectual Property Cooperation

Gene therapyGenomics / NGS

China’s CNIPA Upholds Patent for Nobel-Winning CRISPR/Cas9 Gene Editing Technology

J&JJohnson & Johnson

Abiomed Recalls Over 66,000 Impella Heart Pumps Due to Serious Injury Risk, FDA Classifies as Class I Event

Show More